Arvinas Sets 2026 Milestones as Pipeline Advances, Cash Runway Extends to 2028
Event summary
- Arvinas reports $685.4M in cash reserves as of December 31, 2025, with runway into second half of 2028.
- Randy Teel, Ph.D., appointed as new President and CEO, succeeding John Houston, Ph.D.
- ARV-102 Parkinson’s data accepted for oral presentation at AD/PD Conference in March 2026.
- ARV-806 KRAS G12D degrader completes Phase 1 dose escalation ahead of schedule.
- ARV-6723 immuno-oncology PROTAC set to initiate Phase 1 trial in mid-2026.
The big picture
Arvinas is positioning itself for a transformative year in 2026, with multiple clinical readouts and strategic partnerships shaping its future. The company's focus on targeted protein degradation aligns with broader industry trends toward precision medicine, while its extended cash runway provides flexibility for pipeline advancements. The transition in leadership and ongoing collaborations with Pfizer and Novartis underscore its commitment to maximizing the potential of its PROTAC platform.
What we're watching
- Pipeline Execution
- Whether Arvinas can deliver on multiple value-driving milestones, including data readouts for ARV-102, ARV-806, and ARV-393, in 2026.
- Regulatory Approval
- The pace at which the FDA reviews the NDA for vepdegestrant, with a PDUFA action date of June 5, 2026.
- Cash Management
- How Arvinas will allocate its remaining $685.4M in cash reserves to sustain operations into 2028.
Related topics